Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HCRTR2 | O43614 | 13/20 | 0.38 |
| ▸ | HCRTR1 | O43613 | 10/20 | 0.38 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.34 |
| ▸ | TBXA2R | P21731 | 1/20 | 0.34 |
| ▸ | CA2 | P00918 | 2/20 | 0.33 |
| ▸ | APLNR | P35414 | 1/20 | 0.33 |
| ▸ | TMEM97 | Q5BJF2 | 1/20 | 0.33 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.33 |
| ▸ | TBXAS1 | P24557 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1761274 | 1.00 | HCRTR2 (0.38) | HCRTR2HCRTR1L3MBTL1TBXA2RCA2 | |
| SCHEMBL1030223 | 0.98 | HCRTR2 (0.39) | HCRTR2HCRTR1L3MBTL1TBXA2RCA2 | |
| SCHEMBL1030224 | 0.98 | HCRTR2 (0.39) | HCRTR2HCRTR1L3MBTL1TBXA2RCA2 | |
| SCHEMBL2038232 | 0.98 | HCRTR2 (0.39) | HCRTR2HCRTR1L3MBTL1TBXA2RCA2 | |
| SCHEMBL9162473 | 0.96 | HCRTR2 (0.38) | HCRTR2HCRTR1L3MBTL1TBXA2RCA2 | |
| SCHEMBL5789689 | 0.96 | HCRTR2 (0.38) | HCRTR2HCRTR1L3MBTL1TBXA2RCA2 | |
| SCHEMBL9154429 | 0.96 | HCRTR2 (0.38) | HCRTR2HCRTR1L3MBTL1TBXA2RCA2 | |
| Acetic Acid SCHEMBL21617326 | 0.96 | HCRTR2 (0.38) | HCRTR2HCRTR1L3MBTL1TBXA2RCA2 | |
| Hydrochloric Acid SCHEMBL5195834 | 0.96 | HCRTR2 (0.38) | HCRTR2HCRTR1L3MBTL1TBXA2RCA2 | |
| SCHEMBL9162631 | 0.96 | HCRTR2 (0.38) | HCRTR2HCRTR1L3MBTL1TBXA2RCA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110124677-A1 | AMIDOALKYL-8-AZABICYCLO[3.2.1]OCTANE COMPOUNDS AS MU OPIOID RECEPTOR ANTAGONISTS | THERAVANCE, INC. (US) | 2011-05-26 | — | — | US | disclosed |
| EP-2001876-B1 | 8-AZABICYCLOÝ3.2.1¨OCTANE COMPOUNDS AS MU OPIOID RECEPTOR ANTAGONISTS | THERAVANCE INC (US) | 2011-05-18 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110124677-A1 | AMIDOALKYL-8-AZABICYCLO[3.2.1]OCTANE COMPOUNDS AS MU OPIOID RECEPTOR ANTAGONISTS | OPRM1, OPRL1, OPRK1 | HCRTR2 71/4885HCRTR1 95/4885L3MBTL1 2659/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.